Drugs.com Clinical Trial ResultsOriginal article
AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe Crohn's Disease
Data ReadoutpositiveABBV-466Positive
AI Analysis
Summary
AbbVie presented data showing its investigational dual-targeting therapy ABBV-466 (anti-IL-23 p19 and anti-α4β7) achieved higher endoscopic remission rates than either anti-IL-23 or anti-α4β7 monotherapy in moderate to severe Crohn's disease. The trial phase and quantitative results were not available in the provided text.
Clinical Trial Data
Outcome Details
ABBV-466, a dual-targeting therapy against IL-23 p19 and integrin α4β7, demonstrated higher rates of endoscopic remission than either anti-IL-23 or anti-α4β7 monotherapy in moderate to severe Crohn's disease. Article text is truncated, so specific rates are not provided.
Importance:6/10
Sentiment:
0.60
Crohn's diseaseinflammatory bowel diseaseIL-23integrin α4β7dual-targetingendoscopic remissionclinical dataAbbVie
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on October 19, 2026 7:10 PM